Johnson & Johnson’s IMAAVY Delivers Breakthrough Results in wAIHA
STOCKHOLM, Sweden, June 11, 2026 Johnson & Johnson has reported positive pivotal Phase 2/3 results for IMAAVY® (nipocalimab-aahu) in...
FcRn Inhibitor
Advertisement
Johnson & Johnson IMAAVY Delivers 2-Year gMG Control
HORSHAM, Pa., April 22, 2026 Johnson & Johnson has reported compelling long-term Phase 3 data demonstrating that IMAAVY® (nipocalimab-aahu)...
Johnson & Johnson IMAAVY Shows Strong Phase 3 gMG Data
Horsham, Pennsylvania, USA – April 22, 2026 In a major advancement for autoimmune neurology, Johnson & Johnson has reported...
FDA Grants Fast Track to Nipocalimab for Lupus Treatment
SPRING HOUSE, Pa., March 3, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) Fast Track...
J&J Files FDA Application for IMAAVY in wAIHA
February 24, 2026 – Spring House, Pennsylvania, USA Johnson & Johnson has announced the submission of a supplemental Biologics...
Advertisement
